BMI View: The Czech Republic will continue to be one of the most attractive markets in the CEE region for pharmaceutical and healthcare investment. A strong economic outlook will be the driving factor behind growth, with plans to further increase access to healthcare; pharmaceutical sales are expected to increase over the coming years.
Headline Expenditure Projections
Pharmaceuticals: CZK78.83bn (USD3.01bn) in 2015 to CZK81.10bn (USD3.27bn) in 2016; +2.9% in local currency terms and +8.6 % in US dollar terms. Forecasts in line with last quarter.
Healthcare: CZK284.72bn (USD10.87bn) in 2015 to CZK292.53bn (USD11.79bn) in 2016; +2.7% in local currency terms and +8.4% in US dollar terms. Forecasts in line with last quarter.
|f = BMI forecast. Source: WHO, National Sources, BMI|
|Pharmaceutical sales, USDbn||3.427||3.010||3.268||3.593||3.946||4.122||4.274|
|Pharmaceutical sales, % of GDP||1.80||1.77||1.72||1.67||1.63||1.61||1.58|
|Pharmaceutical sales, % of health expenditure||27.3||27.7||27.7||27.7||27.6||27.4||27.3|
|Health spending, USDbn||12.536||10.871||11.787||12.996||14.319||15.021||15.652|
In Q2 2016, the Czech Republic RRI score has been upgraded slightly from the previous quarter to 63.4 out of 100. The Czech Republic is ranked as the second most attractive market to pharmaceutical investors in the Central and Eastern European (CEE) region within our RRI matrix. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment.
In January 2016, the Czech Republic was represented as one of 23 countries to participate in the first partnership forum for the European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT).
In January 2016, the Association for Bohemian and Moravian Hospitals demanded a 10% annual pay rise for doctors and nurses to prevent their emigration.
In December 2015, the Czech Minister of Health announced plans to improve the population's access to healthcare services, including increased insurer coverage for certain treatments such as pneumococcal vaccinations for elderly citizens and proton beam treatment for certain cancer types.
BMI Economic View
The Czech Republic's economic outlook looks to be strong in comparison to its regional neighbours in the years ahead. The manufacturing and automobile sectors will continue to benefit from recovering eurozone demand and rising consumer confidence domestically.
BMI Political View
Although the Czech Republic will continue to act as an anchor of political stability in central Europe, its dispute with the EU over the reallocation of refugees will lead to mounting tensions. Strong economic growth and an expansionary fiscal policy will give the coalition government continued public support.
The Czech Republic Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
- Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
- Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
- Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
- Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
- Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
- Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
- OTC Drug Market: OTC sales (USDbn & % of total sales).
- Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward Index
BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.